SCHEMBL4110642

SCHEMBL4110642

CNC(=O)Cn1nc(C2CC2)c(Oc2cc(C)c(C#N)c(C)c2)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.41
FFAR4 Q5NUL3 1/20 0.33
ADORA2B P29275 1/20 0.33
SCN9A Q15858 1/20 0.33
ALDH1A1 P00352 2/20 0.32
GLA P06280 1/20 0.32
RAB9A P51151 1/20 0.32
AR P10275 1/20 0.32
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
KDM4E B2RXH2 2/20 0.32
LMNA P02545 1/20 0.32
HSD17B10 Q99714 1/20 0.31
MAPT P10636 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
HCRTR1 O43613 2/20 0.31
HCRTR2 O43614 2/20 0.31
MAPK8 P45983 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4104626 0.90 PGR (0.42) PGRALDH1A1GLARAB9AMEN1
SCHEMBL4107682 0.89 PGR (0.46) PGRALDH1A1GLARAB9AMEN1
SCHEMBL4751253 0.88 PGR (0.40) PGRALDH1A1GLARAB9AMEN1
SCHEMBL4111142 0.85 PGR (0.45) PGRFFAR4ADORA2BSCN9AALDH1A1
SCHEMBL4104566 0.82 PGR (0.46) PGRALDH1A1GLARAB9AMEN1
SCHEMBL4621738 0.81 PGR (0.38) PGRSCN9AALDH1A1MEN1KMT2A
SCHEMBL4748737 0.80 PGR (0.44) PGRALDH1A1GLARAB9AMEN1
SCHEMBL4109845 0.78 PGR (0.44) PGRFFAR4ARHCRTR1HCRTR2
SCHEMBL4102620 0.78 ALDH1A1 (0.35) PGRALDH1A1GLAMEN1KMT2A
SCHEMBL4960690 0.78 PGR (0.35) PGRFFAR4SCN9AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099209-A1 Compounds Useful in Therapy PFIZER INC 2009-04-16 US disclosed
US-20090099209-A1 Compounds Useful in Therapy PFIZER INC 2009-04-16 US disclosed
US-20090099209-A1 Compounds Useful in Therapy PFIZER INC 2009-04-16 US disclosed
US-7482375-B2 Compounds useful in therapy PFIZER INC. (US) 2009-01-27 US disclosed
US-7482375-B2 Compounds useful in therapy PFIZER INC. (US) 2009-01-27 US disclosed
US-7482375-B2 Compounds useful in therapy PFIZER INC. (US) 2009-01-27 US disclosed
US-20060241125-A1 Compounds useful in therapy BRADLEY PAUL A 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241125-A1 Compounds useful in therapy CBR3, GPER1, CBR1 PGR 57/4885FFAR4 1867/4885ADORA2B 1214/4885
US-20090099209-A1 Compounds Useful in Therapy CBR3, CBR1, GPER1 PGR 87/4885FFAR4 2328/4885ADORA2B 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.